PMID- 37414979
OWN - NLM
STAT- MEDLINE
DCOM- 20240126
LR  - 20240206
IS  - 1699-3055 (Electronic)
IS  - 1699-048X (Linking)
VI  - 26
IP  - 2
DP  - 2024 Feb
TI  - Efficacy and safety of trifluridine/tipiracil (TAS-102) in patients with 
      metastatic colorectal cancer: a systematic review and meta-analysis.
PG  - 468-476
LID - 10.1007/s12094-023-03268-5 [doi]
AB  - OBJECTIVES: The purpose of this meta-analysis is to evaluate the efficacy and 
      safety of TAS-102 in treating metastatic colorectal cancer (mCRC) using the most 
      recent data available. METHODS: The literature on the efficacy and safety of 
      TAS-102 versus placebo and/or best supportive care (BSC) in mCRC was obtained 
      through a systematic search of PubMed, Embase, and Web of Science databases 
      through January 2023. Identify the included literature and extract pertinent 
      data, such as the overall survival (OS), progression-free survival (PFS), time to 
      treatment failure (TTF), disease control rate (DCR), incidence of adverse events 
      (AEs) and serious adverse events (SAEs). RESULTS: There were eight eligible 
      articles that included 2903 patients (1964 TAS-102 versus 939 Placebo and/or 
      BSC). In this meta-analysis, TAS-102 treatment resulted in longer OS, PFS, TTF, 
      and higher DCR in patients with mCRC versus placebo and/or BSC. TAS-102 improved 
      OS and PFS in subgroup analyses of mCRC patients with KRAS wild-type and KRAS 
      mutant-type. In addition, TAS-102 did not increase the incidence of serious 
      adverse events. CONCLUSION: TAS-102 can enhance the prognosis of mCRC patients 
      whose standard therapy has failed, regardless of KRAS mutation status, and its 
      safety is acceptable.
CI  - (c) 2023. The Author(s), under exclusive licence to Federacion de Sociedades 
      Espanolas de Oncologia (FESEO).
FAU - Huang, Fengxiang
AU  - Huang F
AUID- ORCID: 0009-0005-2410-0051
AD  - Department of Oncology, The First Affiliated Hospital of Guangxi Medical 
      University, Nanning, China.
FAU - Yang, Haiyan
AU  - Yang H
AD  - Department of Oncology, The First Affiliated Hospital of Guangxi Medical 
      University, Nanning, China.
FAU - Bao, Wenguang
AU  - Bao W
AD  - Department of Oncology, The First Affiliated Hospital of Guangxi Medical 
      University, Nanning, China.
FAU - Bin, Yehong
AU  - Bin Y
AD  - Department of Oncology, The First Affiliated Hospital of Guangxi Medical 
      University, Nanning, China.
FAU - Zhou, Shengsheng
AU  - Zhou S
AD  - Department of Oncology, The First Affiliated Hospital of Guangxi Medical 
      University, Nanning, China.
FAU - Wang, Man
AU  - Wang M
AD  - Department of Oncology, The First Affiliated Hospital of Guangxi Medical 
      University, Nanning, China.
FAU - Lv, Xiaoping
AU  - Lv X
AUID- ORCID: 0000-0001-7144-9508
AD  - Department of Gastroenterology, The First Affiliated Hospital of Guangxi Medical 
      University, Nanning, China. 1612318241@qq.com.
LA  - eng
GR  - 81860104/National Natural Science Foundation of China/
GR  - 2017GXNSFAA198299/Natural Science Foundation of Guangxi Zhuang Autonomous Region/
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20230707
PL  - Italy
TA  - Clin Transl Oncol
JT  - Clinical & translational oncology : official publication of the Federation of 
      Spanish Oncology Societies and of the National Cancer Institute of Mexico
JID - 101247119
RN  - NGO10K751P (tipiracil)
RN  - 0 (trifluridine tipiracil drug combination)
RN  - RMW9V5RW38 (Trifluridine)
RN  - 56HH86ZVCT (Uracil)
RN  - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
RN  - 0 (Drug Combinations)
RN  - 0 (Pyrrolidines)
RN  - QR26YLT7LT (Thymine)
SB  - IM
EIN - Clin Transl Oncol. 2023 Aug 3;:. PMID: 37535184
MH  - Humans
MH  - Trifluridine/adverse effects
MH  - Uracil/adverse effects
MH  - *Colorectal Neoplasms/pathology
MH  - Proto-Oncogene Proteins p21(ras)
MH  - *Colonic Neoplasms/drug therapy
MH  - *Rectal Neoplasms/drug therapy
MH  - Drug Combinations
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - *Pyrrolidines
MH  - *Thymine
OTO - NOTNLM
OT  - Efficacy
OT  - Meta-analysis
OT  - Metastatic colorectal cancer
OT  - Safety
OT  - TAS-102
EDAT- 2023/07/07 01:05
MHDA- 2024/01/26 06:43
CRDT- 2023/07/06 23:29
PHST- 2023/05/22 00:00 [received]
PHST- 2023/06/25 00:00 [accepted]
PHST- 2024/01/26 06:43 [medline]
PHST- 2023/07/07 01:05 [pubmed]
PHST- 2023/07/06 23:29 [entrez]
AID - 10.1007/s12094-023-03268-5 [pii]
AID - 10.1007/s12094-023-03268-5 [doi]
PST - ppublish
SO  - Clin Transl Oncol. 2024 Feb;26(2):468-476. doi: 10.1007/s12094-023-03268-5. Epub 
      2023 Jul 7.